Roche has recorded a successful full year 2017, with sales driven by MS drug Ocrevus and cancer treatments Tecentriq, Perjeta and Alecensa, helping it to boost overall sales by 5% to C
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
